SCHEMBL6701392

SCHEMBL6701392

O=C1c2cc(S(=O)(=O)Nc3cccc(O)c3)ccc2C(=NO)c2cc(S(=O)(=O)Nc3cccc(O)c3)ccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.57
MAPT P10636 3/20 0.56
KMT2A Q03164 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 2/20 0.56
PKM P14618 2/20 0.56
MAPK1 P28482 1/20 0.56
HTT P42858 1/20 0.56
POLB P06746 2/20 0.55
AURKB Q96GD4 8/20 0.55
KDR P35968 7/20 0.55
AURKA O14965 6/20 0.55
MAP4K4 O95819 1/20 0.55
PAK4 O96013 1/20 0.55
PIM1 P11309 1/20 0.55
LTK P29376 1/20 0.55
MAPK14 Q16539 1/20 0.55
LRRK2 Q5S007 1/20 0.55
ALK Q9UM73 1/20 0.55
HSD17B2 P37059 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6701390 1.00 STAT3 (0.57) STAT3MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL6702482 0.97 STAT3 (0.56) STAT3MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL6703746 0.95 AURKB (0.59) STAT3MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL6703748 0.95 AURKB (0.59) STAT3MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL6704528 0.95 AURKB (0.59) STAT3MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL6704050 0.92 AURKB (0.59) STAT3MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL6705029 0.90 STAT3 (0.69) STAT3MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL6702498 0.90 STAT3 (0.69) STAT3MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL6703763 0.87 STAT3 (0.65) STAT3MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL6702771 0.86 HTR6 (0.54) STAT3KMT2APKMPOLBAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693136-B1 DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY ABBOTT LABORATORIES 2004-02-17 US claimed
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS ABBVIE INC. 2004-01-29 US claimed
US-6693136-B1 DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY ABBOTT LABORATORIES 2004-02-17 US disclosed
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS ABBVIE INC. 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS P2RX3, P2RX1, P2RX2 STAT3 3398/4885MAPT 4059/4885KMT2A 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.